Scarica l'app Stockscreener
1.40
2.94%
0.04
Pre-mercato:
1.40
Dare Bioscience Inc Borsa (DARE) Ultime notizie
Daré outlines expanded dual path strategy targeting $4.5B hormone therapy market while accelerating commercialization in Q4 2025 - MSN
Dare Bioscience Inc (DARE) Q4 2025 Earnings Report Preview: What To Expect - GuruFocus
Dare Bioscience Inc expected to post a loss of 43 cents a shareEarnings Preview - TradingView
A Viagra ingredient is now in a topical cream developed for women - Stock Titan
Dare Bioscience (DARE) Expected to Announce Earnings on Monday - Defense World
Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026 - The Manila Times
Daré Bioscience, Inc. to Host Conference Call on March 26, 2026, for Year-End Financial Results and Company Update - Quiver Quantitative
Daré Bioscience to Host Full Year 2025 Financial Results - GlobeNewswire
DARE BIOSCIENCE, INC. Files Form 8-K with SEC Reporting Unregistered Sale of Equity Securities - Minichart
Dare Bioscience secures NIH funding extension for preterm birth therapy - MSN
Dare Bioscience completes closing of Regulation A equity offering - Investing.com
Daré Bioscience Completes Regulation A Preferred Stock Offering - TipRanks
Daré Bioscience (DARE) issues 43,050 preferred-and-warrant units - Stock Titan
Daré Bioscience extends NIH grant period for preterm birth drug By Investing.com - Investing.com Australia
DARE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Dare Bioscience (DARE) Advances Investigational Preterm Birth Tr - GuruFocus
Dare Bioscience receives NIH funding extension for preterm birth treatment By Investing.com - Investing.com Australia
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth - The Manila Times
NIH funds hormone ring as preterm birth lacks FDA-approved treatment - Stock Titan
Daré Bioscience Participates in Virtual Investor “What This Means” Segment - Sahm
Dare Bioscience Participates in Virtual Investor "What This Means" Segment - Bitget
Persistent HPV has no FDA-approved drug; Daré CEO lays out DARE-HPV trial plan - Stock Titan
Daré Bioscience Participates in Virtual Investor 'What This Means” Segment - The Manila Times
Daré Bioscience Completes Second Closing of Regulation A Offering - TipRanks
Daré Bioscience (NASDAQ: DARE) advances Regulation A unit offering - Stock Titan
Daré Bioscience Updates Investor Presentation Under Regulation FD - TipRanks
Daré Bioscience (NASDAQ: DARE) updates investor presentation and furnishes 8-K - Stock Titan
DARE Should I Buy - Intellectia AI
DARE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Daré Bioscience gets FDA clearance for HPV treatment trial By Investing.com - Investing.com India
Daré Bioscience gets FDA clearance for HPV treatment trial - Investing.com Australia
Dare Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - Bitget
Daré Bioscience Announces FDA Clearance of IND for Phase 2 - GlobeNewswire
Dare Bioscience (DARE) CEO subscribes to Reg A units with warrants - Stock Titan
DARE SEC FilingsDare Bioscience Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Dare Bioscience Launches Telehealth Consultations for Women's Arousal Cream - Intellectia AI
Dare Bioscience (DARE) Launches Telehealth for Topical Sildenafi - GuruFocus
First-of-its-kind arousal cream for women offers US-wide telehealth access - Stock Titan
Telehealth Now Available for DARE to PLAY™ Sildenafil - GlobeNewswire
Dare Bioscience Secures Strategic Autonomy with Key Asset Reversion - AD HOC NEWS
Daré Bioscience, Inc. (NASDAQ:DARE): Are Analysts Optimistic? - simplywall.st
Dare Bioscience launches preferred stock and warrant offering on Nasdaq - Investing.com
Daré Bioscience Launches Regulation A Preferred Unit Offering - TipRanks
Companies Like Daré Bioscience (NASDAQ:DARE) Are In A Position To Invest In Growth - Yahoo Finance
Dare Bioscience (NASDAQ:DARE) Share Price Passes Below 50-Day Moving Average – What’s Next? - Defense World
Daré Bioscience issues updated investor corporate presentation - MSN
Daré Bioscience Issues Updated Investor Corporate Presentation - TipRanks
Daré Bioscience, Inc. (NASDAQ:DARE) Q2 2025 Earnings Call Transcript - MSN
Daré targets DARE to PLAY launch in December 2025 as dual path strategy accelerates - MSN
Dare Bioscience secures additional NIAID funding for HPV treatment - MSN
Dare Bioscience Earnings Notes - Trefis
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):